In 2026, driven by policy incentives, consumption upgrades, and technological innovations, the pharmaceutical and food origin contract manufacturing industry is experiencing explosive growth and structural transformation. Serving as the core bridge between traditional Chinese dietary nutrition and the modern health food industry, contract manufacturers have evolved from “simple processors” to “full-chain solution experts.” Compliance, technological advancement, and flexibility have become the dominant trends, marking the industry’s official entry into a golden era of high-quality development.
1.The market scale is experiencing explosive growth, with policy dividends continuously being unleashed.
The food-as-medicine industry has become the most dynamic growth engine in the broader health sector. By 2025, the national end-market size for food-as-medicine products is projected to exceed 370 billion yuan, with the entire industrial chain valued at over 2 trillion yuan and an annual compound growth rate exceeding 20%. The contract manufacturing market size is expected to surpass 80 billion yuan, and the end-market is anticipated to reach 500 billion yuan by 2026. The National List of Food and Drug Substances has been expanded to 106 items, providing a clear foundation for the industry’s supply chain.
Policy support continues to intensify, raising industry compliance thresholds and expanding market opportunities. In early 2026, the National Health Commission, the State Administration for Market Regulation, and the National Administration of Traditional Chinese Medicine jointly promoted the inclusion of “food-as-drug” products in the system of special medical purpose formula foods. Following the implementation of the new national standards in September, these products can directly enter high-value channels such as pharmacies, wellness institutions, and hospital nutrition departments. Concurrently, policies including the compound drug filing pilot program, streamlined approval procedures, and facilitated cross-border customs clearance have further expanded market prospects, providing significant benefits for compliant production capacity.
II. Industry Competitive Landscape: Increased Concentration and Prominent Leader Effect
The domestic pharmaceutical-food dual-use contract manufacturing market currently exhibits characteristics of “total volume expansion, fragmented structure, and concentration among leading players.” Among the nearly 2,000 food contract manufacturers nationwide, fewer than 20% possess SC certification, GMP-compliant facilities, comprehensive traceability systems, and robust formula R&D capabilities; most small and medium-sized manufacturers face challenges such as incomplete qualifications, outdated production processes, and weak R&D capacities.
With tightening regulations and rising quality demands from consumers, the industry is undergoing rapid restructuring: non-compliant small workshops are being phased out, while leading enterprises—boasting comprehensive qualifications, advanced technology, flexible production capacity, and end-to-end service advantages—are continuously expanding their market share, intensifying the “Matthew Effect.” Brand owners are increasingly favoring compliant, traceable source factories capable of rapid customization, driving the industry toward standardization, scale, and specialization.
III. Three Core Trends Defining the New Industry Ecosystem
1.Compliance Establishes the Survival Foundation, Full-Chain Traceability Becomes Standard
By 2026, compliance will be both a mandatory requirement and a core competitive advantage for contract manufacturers. Regulatory authorities have strengthened the mechanism of “strict licensing, full-chain traceability, and dual accountability implementation,” requiring manufacturers to possess an SC production license, a Class 100,000 cleanroom, GMP/ISO 22000 certification, and a raw material traceability system. Following the implementation of the new national standards, higher requirements have been imposed on the authenticity of raw materials, active ingredient content, and production process stability, compelling manufacturers to establish comprehensive quality control and traceability systems covering the entire process—from raw material selection and extraction/concentration to production processing and finished product testing.
2.Technological empowerment drives industrial upgrading, with R&D and smart manufacturing emerging as key competitive barriers.
Industry competition has shifted from “price wars” to “value wars,” where R&D capabilities coupled with smart manufacturing have become the core competitive advantage for leading contract manufacturers.
Innovative Formula Development: Focusing on dual-purpose medicinal and edible compound formulations, active ingredient extraction, and targeted regulation, technologies such as AI-assisted formulation, low-temperature extraction, and sustained-release/controlled-release systems are widely applied to shorten R&D cycles while enhancing product efficacy and competitive differentiation.
Intelligent production: Class 100,000 cleanrooms, automated production lines, digital monitoring systems, and blockchain-based traceability have become standard features, enabling precise control of the production process, stable and traceable quality, and ensuring product safety and consistent quality.
3.Flexible adaptation to diverse needs: One-stop services have become mainstream.
The consumer base exhibits trends toward youthfulness, convenience, and personalization, with urban residents aged 25–40 constituting the primary demographic who prefer ready-to-eat, portable, and fashionable products. Concurrently, there has been a surge in demand for small-batch customization, rapid iteration, and multiple dosage forms.
Contract manufacturers are transitioning from “single-product production” to becoming one-stop full-chain service providers, offering comprehensive services including market research, formula development, dosage form design, customized packaging, regulatory compliance filing, and logistics delivery—fully meeting brands’ needs for “asset-light operations, rapid market entry, and low risk.” Flexible production capacity has become their core advantage; leading companies can handle both small-batch customization (tens of thousands of units) and large-scale production (millions of units) orders simultaneously, with delivery cycles shortened to 7–15 days, enabling rapid response to market changes.
IV. Challenges and Opportunities Coexist; The Key to Breaking the deadlock Lies in Value Enhancement.
The industry still faces significant challenges: high compliance and technological upgrade costs for small and medium-sized factories; intensified competition among leading enterprises resulting in squeezed profits; volatile raw material prices and insufficient supply chain stability; severe product homogenization, and the need for enhanced innovation capabilities.
However, the opportunities are equally significant: consumption upgrading, domestic substitution, cross-border expansion, and policy dividends create vast growth potential. The key to breaking the deadlock for contract manufacturers lies in: 1. Adhering to compliance: improving the qualification system, strengthening quality control and traceability across the entire supply chain, and solidifying safety foundations; 2. Technology empowerment: increasing R&D investment, introducing intelligent equipment, and enhancing product added value and core competitiveness; 3. Deepening services: building flexible supply chains, providing end-to-end solutions, and establishing long-term, mutually beneficial “industry partnership” relationships with brand owners.
V. Future Outlook: A Golden Decade of Value Co-creation
In 2026 and over the next 3–5 years, the pharmaceutical and food ingredient contract manufacturing industry will enter a golden period of high-quality development. Compliance, technological advancement, and flexibility will continue to drive industry transformation, with market concentration further increasing and leading enterprises dominating the industry landscape.
With the rising public awareness of health, the expansion of the healthcare industry, and the international dissemination of traditional Chinese medicine culture, contract manufacturers specializing in food-as-medicine products will achieve greater developmental value and broader growth prospects in safeguarding public health, promoting industrial upgrading, and preserving the wisdom of Chinese dietary therapy.